Sinovac seeks Bangladesh co-financing for vaccine trial: Officials
BSS, Dhaka :
China’s private Sinovac Biotech Ltd has sought Bangladesh’s co-financing for phase-3 clinical trial of its prospective anti-COVID-19 vaccine, more than a month after securing approval to carry out the last phase testing of its inoculate in the country.
“They (Sinovac Biotech Ltd) sent a letter to Bangladesh government seeking co-financing for performing phase-3 human trial,” health division secretary Abdul Mannan told BSS as approached for comments on an unconfirmed report.
He said the government would convey its decision to Sinovac after consulting the matter with relevant organizations and individuals as the Chinese company did not make the proposal when it obtained “our acceptance to carry out the trial”.
“It may take some time to reach a concrete decision on co-funding the vaccine trial . . . (but)
Bangladesh government is sincerely thinking about the matter keeping in mind the issue of public benefits,” Mannan said.
Directorate General of Health Services (DGHS) chief Professor Dr Abul Bashar Mohammad Khurshid Alam said Sinovac’s the new proposal came when Bangladesh exhausted required steps to launch the trial.
“Bangladesh government, however, is still positive about carrying out final trial of coronavirus vaccine developed by the Chinese company” as it emerged as a forerunner in the global race for developing a coronavirus vaccine, the DGHS director general said.
The company channeled their original proposal to Bangladesh through Dhaka-based International Centre for Diarrheal Disease Research, Bangladesh (icddr’b) and obtained the health authorities final clearance on August 27 while officials familiar with the fresh development said they received Sinovac’s proposal seeking the co-funding on September 22.
Officials earlier said Bangladesh government gave the approval for the clinical trial of the vaccine in Bangladesh after examining all necessary research protocols including effectiveness and safety issues involving the inoculate.
China’s private Sinovac Biotech Ltd has sought Bangladesh’s co-financing for phase-3 clinical trial of its prospective anti-COVID-19 vaccine, more than a month after securing approval to carry out the last phase testing of its inoculate in the country.
“They (Sinovac Biotech Ltd) sent a letter to Bangladesh government seeking co-financing for performing phase-3 human trial,” health division secretary Abdul Mannan told BSS as approached for comments on an unconfirmed report.
He said the government would convey its decision to Sinovac after consulting the matter with relevant organizations and individuals as the Chinese company did not make the proposal when it obtained “our acceptance to carry out the trial”.
“It may take some time to reach a concrete decision on co-funding the vaccine trial . . . (but)
Bangladesh government is sincerely thinking about the matter keeping in mind the issue of public benefits,” Mannan said.
Directorate General of Health Services (DGHS) chief Professor Dr Abul Bashar Mohammad Khurshid Alam said Sinovac’s the new proposal came when Bangladesh exhausted required steps to launch the trial.
“Bangladesh government, however, is still positive about carrying out final trial of coronavirus vaccine developed by the Chinese company” as it emerged as a forerunner in the global race for developing a coronavirus vaccine, the DGHS director general said.
The company channeled their original proposal to Bangladesh through Dhaka-based International Centre for Diarrheal Disease Research, Bangladesh (icddr’b) and obtained the health authorities final clearance on August 27 while officials familiar with the fresh development said they received Sinovac’s proposal seeking the co-funding on September 22.
Officials earlier said Bangladesh government gave the approval for the clinical trial of the vaccine in Bangladesh after examining all necessary research protocols including effectiveness and safety issues involving the inoculate.
